Stroke guidelines
Reading File
Asking for Preferences
Finding Sources
Searching PubMed
"ischemic stroke"[MeSH Terms] AND "guidelines"
Searching the Web
AHA ASA ischemic stroke acute management guidelines 2024 2025
Reading File
Reading File
Reading Web Page
https://www.ahajournals.org/doi/10.1161/STR.0000000000000513
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple textbooks and the brand-new 2026 AHA/ASA guideline. Let me compile a thorough response.
Acute Ischemic Stroke (AIS) - Management Guidelines
Important update: The AHA/ASA released a 2026 Guideline for the Early Management of Patients with Acute Ischemic Stroke (replaces the 2018 guideline and its 2019 update). Key changes are noted below.
1. Initial Evaluation & Stabilization
Prehospital / ED arrival priorities:
- Activate stroke team immediately; aim for door-to-needle time <60 minutes for tPA
- Airway, breathing, circulation assessment; pulse oximetry; supplemental O2 if SpO2 <94%
- Avoid hyperthermia (worsens ischemic outcome); treat fever aggressively
- 12-lead ECG + troponin on arrival (cardiac monitoring for at least 48 h; 3-20% of strokes have concomitant myocardial ischemia)
- Blood work: CBC, PT/INR, aPTT, BMP, glucose
Imaging:
- Non-contrast CT (NCCT) head immediately - rules out hemorrhage
- CT angiography (CTA) ± CT perfusion for thrombectomy candidates or extended-window thrombolysis
Stroke units: All stroke/TIA patients presenting within 72 h should be admitted, preferably to a dedicated stroke unit (associated with lower mortality, shorter LOS, less nursing home discharge).
2. Blood Pressure Management
| Clinical scenario | BP target |
|---|---|
| Pre-tPA | Must be <185/110 mmHg before giving tPA; use IV labetalol or nicardipine |
| Post-tPA (first 24 h) | Maintain <180/105 mmHg |
| Not receiving tPA, no reperfusion | Permissive hypertension; avoid lowering unless >220/120 mmHg |
| Post-EVT | Target SBP 130-180 mmHg (post-2026 guidance) |
Optimal SBP in the acute phase without intervention appears to be 160-200 mmHg - overtreating causes hypotension and worsens ischemic penumbra. Autoregulation is impaired.
3. IV Thrombolysis (tPA / Alteplase)
Dosing
Alteplase 0.9 mg/kg IV (max 90 mg); 10% as bolus over 1 min, remainder over 60 min.
Time windows and eligibility (2019/2026 AHA/ASA)
| Window | Recommendation |
|---|---|
| 0-3 hours | Recommended for all eligible patients ≥18 years (including >80 years, severe stroke, mild-disabling stroke) |
| 3-4.5 hours | Recommended for patients ≤80 years, no history of both DM + prior stroke, NIHSS ≤25, not on OAC, and infarct not involving >1/3 MCA territory |
| 4.5-9 hours (extended, new 2026) | Reasonable (COR 2a) if salvageable penumbra on automated perfusion imaging AND either (a) wake-up stroke within 9 h of sleep midpoint or (b) 4.5-9 h from last known well |
Key exclusions
- BP >185/110 mmHg (untreatable)
- Active internal bleeding, recent major surgery <14 days
- Recent intracranial or spinal surgery, head trauma, or stroke <3 months
- Platelet count <100,000; INR >1.7; aPTT elevated
- Direct thrombin or Xa inhibitors: do NOT give tPA unless aPTT, INR, platelet count are normal or last dose >48 h ago (normal renal function)
- LMWH full treatment dose within previous 24 h: contraindicated
- Prior ICH
Symptomatic ICH risk
Occurs in 2-7% post-tPA; highest in most severe strokes. Usually within 36 h (50% within 5-10 h). Asymptomatic ICH is more frequent.
4. Tenecteplase - 2026 Update
The 2026 guideline now endorses tenecteplase as an alternative to alteplase for patients without large vessel occlusion (LVO). A 2024 meta-analysis (PMID: 39413337) of RCTs showed tenecteplase is non-inferior to alteplase within 4.5 hours. Tenecteplase is given as a single IV bolus (0.25 mg/kg, max 25 mg), which simplifies administration.
5. Endovascular Thrombectomy (EVT)
Standard window: 0-6 hours (COR 1 - Strong recommendation)
Criteria (2026 AHA/ASA):
- Anterior circulation proximal LVO (ICA or M1 segment)
- NIHSS ≥6
- Prestroke mRS 0-1
- ASPECTS 3-10 (note: 2026 expanded from prior ASPECTS ≥6 threshold)
- Perform regardless of whether tPA was given
Extended window: 6-24 hours
| Window | Trial | Criteria |
|---|---|---|
| 6-16 h | DAWN, DEFUSE 3 | Clinical-imaging mismatch (age/NIHSS/core infarct volume criteria); anterior circulation LVO |
| 16-24 h | DAWN | Age ≥80 + NIHSS ≥10 + core <21 mL; or age <80 + NIHSS ≥10 + core <31 mL; or age <80 + NIHSS ≥20 + core <51 mL |
Time is critical: Each 1-hour delay to reperfusion = measurably worse functional outcome. After 7 hours from onset, benefit becomes non-significant in pooled data.
Distal/posterior circulation occlusions: Benefits are less certain for M2/M3 MCA, ACA, vertebral, basilar, or PCA occlusions (basilar is often treated despite limited evidence given the devastating natural history).
6. Glucose Management
- Treat hypoglycemia immediately (glucose <60 mg/dL mimics stroke)
- Avoid hyperglycemia but intensive insulin control is NOT recommended - the SHINE Trial showed no benefit and increased hypoglycemia risk
- Optimal target glucose in acute stroke remains uncertain
7. Cerebral Edema Management
- Edema peaks at 72-120 hours post-stroke
- Corticosteroids are NOT indicated for ischemic cerebral edema (no proven benefit, increase infections)
- Osmotherapy (mannitol, hypertonic saline) for raised ICP
- Hemicraniectomy: Decompressive surgery within 48 h is life-saving for malignant MCA infarction (large dominant/non-dominant hemisphere strokes), particularly in younger patients
8. Antiplatelet / Antithrombotic Therapy
- Aspirin 325 mg within 24-48 h of stroke onset (not within 24 h of tPA)
- Dual antiplatelet (aspirin + clopidogrel) for 21 days for minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4), then transition to monotherapy - based on POINT and CHANCE trials
- Anticoagulation: Not recommended for acute cardioembolic stroke in first 24-48 h if large infarct (hemorrhagic transformation risk); timing depends on infarct size and source
9. Key Time Metrics (AHA/ASA targets)
| Metric | Target |
|---|---|
| Door-to-CT | ≤25 minutes |
| Door-to-needle (tPA) | ≤60 minutes |
| Door-to-groin puncture (EVT) | ≤90 minutes |
| Symptom onset to treatment | As fast as possible - "time is brain" |
Sources
- Bradley and Daroff's Neurology in Clinical Practice, p. 1405-1406
- Rosen's Emergency Medicine, p. 1435-1439 (Table 87.5: 2019 AHA/ASA Alteplase Guidelines)
- 2026 AHA/ASA Guideline for Early Management of AIS (ahajournals.org) - replaces 2018 guideline
- Palaiodimou et al. 2024, Neurology - Tenecteplase vs Alteplase meta-analysis [PMID: 39413337]
This is a shared conversation. Sign in to Orris to start your own chat.